For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?

Affiliations

¹ Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
² Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
³ Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China; Hepatology Institute, Peking University People's Hospital, Beijing, China. Electronic address: lu.fengmin@hsc.pku.edu.cn.

Comment

Xin Liu et al. J Hepatol. 2024 Jan.

. 2024 Jan;80(1):e31-e32.

doi: 10.1016/j.jhep.2023.05.026. Epub 2023 Jun 9.

¹ Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
² Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
³ Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China; Hepatology Institute, Peking University People's Hospital, Beijing, China. Electronic address: lu.fengmin@hsc.pku.edu.cn.

No abstract available

Comment in

Reply to: "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
Lai JC, Wong GL, Yip TC. Lai JC, et al. J Hepatol. 2024 Jan;80(1):e32-e34. doi: 10.1016/j.jhep.2023.10.003. Epub 2023 Oct 10. J Hepatol. 2024. PMID: 37821018 No abstract available.

Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC, Wong VW, Lai MS, Lai JC, Hui VW, Liang LY, Tse YK, Chan HL, Wong GL. Yip TC, et al. J Hepatol. 2023 Mar;78(3):524-533. doi: 10.1016/j.jhep.2022.11.020. Epub 2022 Dec 2. J Hepatol. 2023. PMID: 36463985